RTD-01

RTD-01 is a synthetic peptide research compound designed as a triple receptor agonist, exhibiting binding activity at GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. The simultaneous engagement of all three incretin and glucagon receptor subtypes positions RTD-01 as a research tool for investigating the intersecting signalling pathways that govern metabolic homeostasis, energy balance, and pancreatic beta-cell function in controlled experimental models.

In vitro applications of triple receptor agonist peptides have included receptor binding assays, cAMP accumulation studies, and functional characterisation of downstream signalling cascades in pancreatic, hepatic, and hypothalamic cell lines. RTD-01 is of research interest in the study of co-agonism pharmacology, receptor cross-talk mechanisms, and the comparative evaluation of mono-, dual-, and triple-agonist activity profiles. Pre-clinical studies in rodent models have characterised the metabolic effects of this class of compound under controlled experimental conditions.

Pepti-Genix supplies RTD-01 as a lyophilised white powder in two research quantities, independently verified at ≥99% purity by HPLC analysis. A Certificate of Analysis confirming identity and purity is included with every order. This compound is supplied strictly for in vitro laboratory research purposes only. It is not intended for human or veterinary use, consumption, injection, or administration of any kind.